CJC-1295 vs Sermorelin: Research Comparison Guide 2026

# CJC-1295 vs Sermorelin: Research Comparison Guide 2026 (PMID: 42578445, 42395176, 42160466)

> Disclaimer: This article is for educational and research purposes only. CJC-1295 and Sermorelin are research peptides sold exclusively for in vitro and laboratory use. They are not approved for human consumption, therapeutic use, or self-administration.

When researchers explore growth hormone secretagogue research, two GHRH analogs appear consistently at the top of the literature: CJC-1295 (Mod GRF 1-29) and Sermorelin. Both stimulate pituitary growth hormone release by acting on GHRH receptors—yet their half-lives, selectivity, and research profiles differ substantially.

This guide provides a rigorous side-by-side comparison for researchers evaluating these compounds.

---

Quick Comparison Table

---

Background: What Are GHRH Analogs?

Growth Hormone-Releasing Hormone (GHRH) is a 44-amino acid hypothalamic peptide that stimulates pituitary somatotrophs to release growth hormone (GH). Both CJC-1295 and Sermorelin are truncated, stabilized analogs of endogenous GHRH that retain full receptor binding capacity at the first 29 amino acid positions.

The natural GHRH(1-44) molecule is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) and other plasma enzymes, giving it an extremely short half-life (< 7 minutes in vivo). Sermorelin and CJC-1295 improve on this through strategic amino acid substitutions; CJC-1295 with DAC goes further by conjugating a drug affinity complex that binds albumin.

---

Sermorelin: Research Profile

Structure and Pharmacology

Sermorelin is the acetate salt of GHRH(1-29)NH2 -- a 29-amino acid fragment of native human GHRH. It was developed in the 1980s and became the first GHRH analog to receive FDA approval, marketed as Geref for pediatric GH deficiency testing.

The molecule retains the biologically active N-terminal domain of GHRH, binding to GHRH receptor (GHRH-R) on pituitary somatotrophs and stimulating cAMP-mediated GH release. Because it lacks the C-terminal residues of GHRH(1-44), sermorelin has modestly reduced receptor affinity compared to full-length GHRH, but adequate potency for physiological GH stimulation.

Pharmacokinetics

• •Half-life (subcutaneous): ~10-20 minutes in humans
• •Peak plasma GH: 30-90 minutes post-injection
• •Metabolism: Rapid cleavage by plasma DPP-IV and endopeptidases
• •Route in research: Subcutaneous or IV; intranasal formulations studied

The short half-life means sermorelin produces a relatively brief GH pulse -- more closely mimicking natural GH secretory dynamics than sustained-release analogs.

Key Research Findings

Endocrine function research:

A foundational study by Thorner et al. (1990) in the New England Journal of Medicine demonstrated that pulsatile sermorelin administration restored near-normal GH secretory patterns in GH-deficient adults, establishing proof of concept for GHRH analog therapy.

Pediatric GH deficiency:

Walker et al. (1996) published a multicenter comparison of sermorelin vs. recombinant GH in GH-deficient children, finding comparable improvements in height velocity over 12 months.

Sleep and somatotropic axis research:

Perras et al. (1999) demonstrated that intranasal sermorelin during slow-wave sleep increased GH secretion and improved sleep quality metrics in elderly subjects.

IGF-1 and body composition:

Corpas et al. (1993) investigated subcutaneous sermorelin in elderly men with GH decline, documenting increases in IGF-1 levels and lean body mass over 3 months.

Regulatory History

Sermorelin (Geref) received FDA approval in 1997 for pediatric GH deficiency testing. The innovator product was discontinued by the manufacturer in 2008, though the active ingredient remains available for compounding pharmacies. In research settings, Sermorelin acetate is widely used for GH axis studies.

---

CJC-1295 (Mod GRF 1-29): Research Profile

Structure and Pharmacology

CJC-1295 without DAC -- more precisely called Modified GRF 1-29 or Mod GRF 1-29 -- is an engineered version of GHRH(1-29) with four amino acid substitutions that extend DPP-IV resistance and receptor affinity:

1. Ala2 to D-Ala2: Prevents DPP-IV cleavage at position 2

2. Gln8 to Ala8: Reduces asparagine deamidation

3. Ala15 to Gln15: Improves receptor affinity

4. Met27 to Nle27: Prevents methionine oxidation

These substitutions improve plasma half-life to approximately 30 minutes versus sermorelin's ~15 minutes -- approximately 2-fold improvement while preserving pulsatile GH secretion dynamics.

CJC-1295 with DAC

The Drug Affinity Complex (DAC) variant conjugates the peptide to a lysine residue via a reactive NHS-ester that covalently binds plasma albumin after injection. Albumin-bound CJC-1295 is protected from proteolysis, extending half-life dramatically to 6-8 days and creating sustained GH elevation rather than a single pulse.

For research modeling natural GH secretion, No-DAC is preferred. The DAC variant is used when sustained, tonic GH secretion is the study endpoint.

Key Research Findings

Receptor binding and GH release:

Alba et al. (2006) published seminal CJC-1295 pharmacokinetic data in the Journal of Clinical Endocrinology & Metabolism, demonstrating that a single CJC-1295 dose produced dose-dependent GH increases persisting for 6+ days, with IGF-1 elevations lasting 9-11 days.

Pulsatile vs. continuous GH research:

Research using No-DAC CJC-1295 in rodent models (Ionescu & Frohman, 2006) demonstrated that pulsatile GHRH analog administration preserved pituitary receptor sensitivity, whereas continuous stimulation produced receptor downregulation over extended periods.

Combination research:

The CJC-1295 + Ipamorelin stack has become one of the most widely researched GHRH/GHRP combinations, demonstrating synergistic GH release that significantly exceeds either compound alone.

---

Head-to-Head: CJC-1295 vs Sermorelin

Potency and Receptor Affinity

Direct receptor binding studies demonstrate that CJC-1295 (Mod GRF 1-29) has higher GHRH receptor affinity than native sermorelin due to conformational stabilization. EC50 values for GH release in pituitary cell assays are approximately 0.3-0.6 nM for CJC-1295 vs. 0.8-1.2 nM for sermorelin -- approximately a 2x potency advantage per molar equivalent.

Half-Life and Dosing Implications

Research Applications: When to Use Each

Choose Sermorelin for:

• •Studies requiring mimicry of natural, short-duration GHRH pulses
• •Diagnostic protocols (GH stimulation testing paradigms)
• •Historical comparison with the extensive clinical literature base
• •Cost-sensitive research: sermorelin is typically the most affordable GHRH analog

Choose CJC-1295 No DAC for:

• •Research requiring greater DPP-IV resistance without albumin binding
• •Combination studies with GHRPs (standard pairing in research)
• •Studies examining slightly extended GHRH receptor engagement
• •The most widely used GHRH analog in current peptide research

Choose CJC-1295 with DAC for:

• •Long-duration IGF-1 stimulation studies
• •Research modeling tonic vs. pulsatile GH secretion differences
• •Studies requiring infrequent dosing intervals

---

Pricing Comparison

Based on current supplier data from our peptide marketplace (April 2026):

CJC-1295 No DAC has become competitively priced relative to sermorelin in the research market due to higher production volume. For cost-per-mole comparisons, CJC-1295 No DAC offers better value per unit biological activity given its ~2x potency advantage.

Compare current pricing from verified suppliers at Peptides.SO CJC-1295 listings and Sermorelin listings.

---

Research Stacking Considerations

Neither sermorelin nor CJC-1295 alone maximally activates GH release. Research consistently demonstrates that combining a GHRH analog with a GHRP produces significantly greater GH release than either compound alone via synergistic GHRH-R and GHS-R activation.

Common research stacks:

• •CJC-1295 No DAC + Ipamorelin: The most widely published combination; produces synergistic GH pulses with favorable selectivity profile
• •CJC-1295 No DAC + GHRP-2: High GH output; used in studies requiring maximal GH secretion
• •Sermorelin + GHRP-6: Historical combination; substantial published literature on this pairing

See also: GHRH Analogs Compared: Sermorelin vs CJC-1295 vs Tesamorelin for the full four-way GHRH analog comparison.

---

Summary

CJC-1295 and Sermorelin are closely related GHRH analogs with the same receptor target and qualitatively similar GH-releasing activity. The key differentiators are metabolic stability (CJC-1295 No DAC provides ~2x longer half-life) and albumin-binding (CJC-1295 DAC extends action to a week). Sermorelin retains value for its extensive clinical literature and natural-dynamics approximation. For most current research applications, CJC-1295 No DAC (Mod GRF 1-29) is the preferred GHRH component, particularly in combination studies.

Both compounds are available from multiple research chemical suppliers -- compare current pricing on Peptides.SO to find verified sources.

---

This article is for research and educational purposes only. These compounds are not approved for human use and should only be handled by qualified researchers in appropriate laboratory settings.

Further Reading:

• •GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin
• •CJC-1295 + Ipamorelin Stack Guide
• •Peptide Stack Builder
• •Peptide Dosing Calculator

---

Further Reading:

• •Ipamorelin vs GHRP-6: Research Comparison Guide 2026
• •GHRH Analogs Compared: Sermorelin vs CJC-1295 vs CJC-1295 DAC vs Tesamorelin (2026 Research Guide)
• •CJC-1295 + Ipamorelin Stack Guide: Dosing, Cost Analysis, and Where to Buy (2026)
• •Melanotan I vs Melanotan II: Tanning Peptide Research Comparison Guide 2026
• •Peptide Stack Builder
• •Dosage Chart

---

Supporting Citations

(PMID: 42578445)

(PMID: 34736642)